Global Urinalysis Market - Forecasts from 2024 to 2029

Global Urinalysis Market - Forecasts from 2024 to 2029

The global urinalysis market is expected to grow at a compound annual growth rate of 5.86% over the forecast period to reach a market size of US$4.489 billion in 2029 from US$3.015 billion in 2022.

Urinalysis is a urine test that is used to diagnose and treat a variety of conditions, including urinary tract infections (UTI), kidney disease, and diabetes. During a urinalysis, the appearance, concentration, and content of urine are all evaluated. Abnormal urine findings may indicate a condition or illness. In September 2021, according to Eurek Aert, the Translational Genomics Research Institute (TGen), a City of Hope affiliate, discovered a method to pinpoint early-stage cancer by utilizing Urinalysis to analyze small strands of cell-free DNA in urine. Various non-invasive urine automated analyzers have been developed to provide rapid and accurate test results.

The increased prevalence of UTIs, diabetes, and kidney and liver disorders, as well as the growing geriatric population and the resulting increase in age-related diseases, are driving market expansion. In hospitals and other critical care units and medical-surgical units, the prevalence of conditions such as UTI, renal disease, and diabetes is likely to be greater. According to the National Centre of Biotechnology Information, one-third of women will have experienced a UTI by the age of 24 and half by the age of 32.

Additionally, according to the International Diabetes Federation, about 463 million individuals between the age of 20-79 years had diabetes in 2019, and this number is expected to grow to 700 million by 2045. Furthermore, according to the National Kidney Foundation, chronic kidney disease (CKD) affects 10% of the world's population, with millions dying each year.

However, the market expansion is likely to be hampered in the coming years by a strict regulatory framework and an unfavorable reimbursement condition.

Market Drivers:

Rising geriatric population and age-related diseases are anticipated to increase the global urinalysis market.

The growing geriatric population in developed and developing countries will boost the urinalysis market growth. According to the World Health Organization, the number of adults aged 60 and more will surpass children under the age of five by 2020. The prevalence of age-related diseases such as diabetes and kidney and liver disease is projected to rise dramatically as the geriatric population grows.

According to the International Diabetes Organization, one in every five persons over the age of 65 has diabetes. Prescriptions for tests such as creatinine, albumin, glucose, ketones, and bilirubin, among others, are on the rise as a result of the increased diagnosis and treatment of such disorders, which is benefiting urinalysis, which is used to perform these tests.

Market Restraints:

Unfavorable reimbursement conditions could hamper the global urinalysis market.

The availability of refurbished instruments, which provide the same functionality as new equipment at a cheaper cost, poses a barrier to market growth. Several end customers, primarily small and medium-sized laboratories, choose cost-effective reconditioned equipment. Particularly in developing nations, where markets are price-sensitive, inexpensive instruments with equivalent functions are preferred. This is likely to limit the revenue of companies that sell branded analyzers, thus limiting the market growth.

The North American region is projected to have a significant marketplace.

Due to an aging population and a high prevalence of CKD, the North American market is projected to have a significant market position. Kidney failure, high blood pressure, and diabetes are all linked to CKD. According to the National Kidney Foundation, more people die due to CKD than breast cancer and prostate cancer each year. In the United States, kidney disease is a major cause of death. It now affects around 37 million individuals in the US. It is more common in the aging population, affecting around 15% of the adult population.

Kidney disease affects around one in every three individuals with diabetes and one in every five adults with high blood pressure. Hence, there is a growing demand for accurate detection and treatment of CKD, and these factors are likely to drive up demand for urinalysis.

Key Developments:

December 2023- Siemens Healthineers introduced the Atellica UAS 60 Analyzer, a digital solution for urine sediment analysis. This automated tool replaces manual microscopy, enabling quicker and more accurate results review and reporting. It generates 15 high-resolution digital images per sample, features auto Image Evaluation Module technology for automatic identification of particles, live-view mode for movement visualization, and automatic bacterial subcategorization for easier identification of CKD and UTI.
November 2022- EmeritusDX and KDx Diagnostics Inc. partnered to offer the URO17 non-invasive urine test for bladder cancer detection. URO17 is a highly sensitive and negative predicted value (NPV) test that can determine the status of active bladder cancer and improve patient diagnosis. It is available as a Laboratory Developed Test in the US, allowing EmeritusDX to offer URO17 testing to Urology practices nationwide. The test can rule out patients with micro-hematuria for unnecessary cystoscopy and reduce the work-up.
October 2022- Olive Diagnostics, an IoMT MedTech startup, received the European CE Mark for its innovative AI-based urine analysis device, the Olive KG. The device is the world's first hands-free, non-invasive, AI-based optical device for passive and seamless urinalysis mounted on any toilet. It performs high-quality analysis of important parameters in patients' urine without user intervention, measuring red blood cells, proteins, Nitrites, pH levels, volume, pressure, color, and frequency of urination. The device generates real-time personal data, secured according to GDPR and HIPPA requirements, which is sent to the cloud and treated by the treating physician.
September 2022- Sysmex Corporation introduced the UF-1500 Fully Automated Urine Particle Analyzer (UF-1500), a new product for urine sediment testing. The UF-1500 inherits the functionality and usability of the UF-5000 model but is downsized. It offers a wider range of solutions tailored to customers' environments and contributes to streamlining and standardization of urine testing at small and medium-sized facilities. The UF-1500 supports connectivity with transportation systems for urine chemistry analyzers, meeting various customer needs, including demand from small and medium-sized facilities and backup systems from large facilities.

Market Segmentation:

By Product Type
Instruments
Automated Urine Analyzer
Semi-automated Urine Analyzer
Point-of-Care Urine Analyzer
Consumables
Reagents
Kits
Dipsticks
Disposables
By Test Type
Biochemical Urinalysis
Pregnancy & Fertility Urinalysis
Sediment Urinalysis
By Application
Urinary Tract Infections
Diabetes
Kidney Diseases
Liver Diseases
Pregnancy and Fertility
Others
By End-User
Hospitals & Clinics
Diagnostic Laboratories
Research & Academic Institutions
Home Care Settings
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
UK
Italy
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
South Africa
Others
Asia Pacific
China
India
Japan
South Korea
Taiwan
Thailand
Indonesia
Others